# EDGAR Filing Document

**Accession Number:** 0001496443
**File Stem:** 0001683168-26-003762
**Filing Date:** 2026-5
**Character Count:** 113256
**Document Hash:** f32359438813a85a5d0e7fe1f0b09610
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-003762.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001683168-26-003762

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 59

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Paysign, Inc.
- **CENTRAL INDEX KEY:** 0001496443
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-BUSINESS SERVICES, NEC [7389]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 954550154
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38623
- **FILM NUMBER:** 26970959

**BUSINESS ADDRESS:**
- **STREET 1:** 2615 ST. ROSE PARKWAY
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89052
- **BUSINESS PHONE:** 702-453-2221

**MAIL ADDRESS:**
- **STREET 1:** 2615 ST. ROSE PARKWAY
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89052

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 3PEA INTERNATIONAL, INC.
- **DATE OF NAME CHANGE:** 20100713

?xml version='1.0' encoding='ASCII'? PAYSIGN, INC. 10-Q

[**Table of Contents**](#q1_001)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 10-Q**

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2026

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to __________

Commission file number 001-38623

**PAYSIGN, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **95-4550154** |
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) |

---

**2615 St. Rose Parkway, Henderson, Nevada 89052**

(Address of principal executive offices) (Zip code)

**(702) 453-2221**

(Registrant's telephone number, including area code)

**N/A**

(Former name, former address and former fiscal year, if changed since last report)

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | PAYS | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 55,905,773 shares as of May 6, 2026.

PAYSIGN, INC.

FORM 10-Q REPORT

INDEX

---

| | |
|:---|:---|
| [PART I. FINANCIAL INFORMATION](#q1_002) |  |
| &nbsp;&nbsp;&nbsp;[Item 1. Financial Statements](#q1_003) | 3 |
| &nbsp;&nbsp;&nbsp;[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#q1_009) | 20 |
| &nbsp;&nbsp;&nbsp;[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#q1_010) | 28 |
| &nbsp;&nbsp;&nbsp;[Item 4. Controls and Procedures](#q1_011) | 28 |
| [PART II. OTHER INFORMATION](#q1_012) |  |
| &nbsp;&nbsp;&nbsp;[Item 1. Legal Proceedings](#q1_013) | 29 |
| &nbsp;&nbsp;&nbsp;[Item 1A. Risk Factors](#q1_014) | 29 |
| &nbsp;&nbsp;&nbsp;[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#q1_015) | 29 |
| &nbsp;&nbsp;&nbsp;[Item 5. Other Information](#q1_016) | 29 |
| &nbsp;&nbsp;&nbsp;[Item 6. Exhibits](#q1_017) | 30 |
| [SIGNATURES](#q1_018) | 31 |

---

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements.**

**PAYSIGN, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026**<br> **(Unaudited)** | **December 31,<br> 2025**<br> **(Audited)** |
| ASSETS |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $20545119 | $21067651 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 158950332 | 143917060 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 94248593 | 72191994 |
| &nbsp;&nbsp;&nbsp;Other receivables | 345228 | 926529 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 3265549 | 1953717 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 277354821 | 240056951 |
| Fixed assets, net | 2007393 | 1897892 |
| Intangible assets, net | 21675898 | 22346213 |
| Goodwill | 4487637 | 4487637 |
| Operating lease right-of-use asset | 5522775 | 5729541 |
| Deferred tax asset, net | 1677104 | 1734969 |
| Total assets | $312725628 | $276253203 |
| LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | $87539193 | $70542803 |
| &nbsp;&nbsp;&nbsp;Customer card funding | 158112295 | 143191068 |
| &nbsp;&nbsp;&nbsp;Operating lease liability, current portion | 871495 | 751503 |
| &nbsp;&nbsp;&nbsp;Other liabilities, current portion | 1585985 | 1863116 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 248108968 | 216348490 |
| Operating lease liability, long-term portion | 5048579 | 5273891 |
| Other liabilities, long-term portion | 4554666 | 6140651 |
| Total liabilities | 257712213 | 227763032 |
| Commitments and contingencies (Note 9) | **–** | **–** |
| Stockholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock: $0.001 par value; 25,000,000 shares authorized; none issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Common stock; $0.001 par value; 150,000,000 shares authorized, 56,732,596 and 56,021,596 issued at March 31, 2026 and December 31, 2025, respectively | 56733 | 56022 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 36786545 | 35503253 |
| &nbsp;&nbsp;&nbsp;Treasury stock at cost, 990,955 and 934,708 shares, respectively | (2348392) | (2148715) |
| &nbsp;&nbsp;&nbsp;Retained earnings | 20518529 | 15079611 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 55013415 | 48490171 |
| Total liabilities and stockholders' equity | $312725628 | $276253203 |

---

See accompanying notes to unaudited condensed consolidated financial statements.

**PAYSIGN, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended**<br> **March 31,** | **Three Months Ended**<br> **March 31,** |
|  | **2026** | **2025** |
| Revenues |  |  |
| &nbsp;&nbsp;&nbsp;Plasma industry | $11748611 | $9409880 |
| &nbsp;&nbsp;&nbsp;Pharma industry | 15679452 | 8618653 |
| &nbsp;&nbsp;&nbsp;Other | 610361 | 569616 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 28038424 | 18598149 |
| Cost of revenues | 9819479 | 6907321 |
| Gross profit | 18218945 | 11690828 |
| Operating expenses |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 8914654 | 7400759 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 2636156 | 1801003 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 11550810 | 9201762 |
| Income from operations | 6668135 | 2489066 |
| Other income |  |  |
| &nbsp;&nbsp;&nbsp;Interest income, net | 800863 | 762198 |
| Income before income tax provision | 7468998 | 3251264 |
| Income tax provision | 2030080 | 665164 |
| Net income | $5438918 | $2586100 |
| Net income per share |  |  |
| &nbsp;&nbsp;&nbsp;Basic | $0.10 | $0.05 |
| &nbsp;&nbsp;&nbsp;Diluted | $0.09 | $0.05 |
| Weighted average common shares |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 55167911 | 53576030 |
| &nbsp;&nbsp;&nbsp;Diluted | 61022060 | 55142511 |

---

See accompanying notes to unaudited condensed consolidated financial statements.

**PAYSIGN, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(UNAUDITED)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | **Treasury Stock** | **Treasury Stock** | | |
|  | **Shares** | **Amount** | **Additional <br> Paid-in**<br>**Capital** | **Shares** | **Amount** | **Retained**<br>**Earnings** | **Total Stockholders'**<br>**Equity** |
| Balance, December 31, 2025 | 56021596 | $56022 | $35503253 | (934708) | $(2148715) | $15079611 | $48490171 |
| &nbsp;&nbsp;&nbsp;Stock issued upon vesting of restricted stock | 711000 | 711 | (711) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation |  |  | 1284003 |  |  |  | 1284003 |
| &nbsp;&nbsp;&nbsp;Repurchase of common stock |  |  |  | (56247) | (199677) |  | (199677) |
| &nbsp;&nbsp;&nbsp;Net income | – | – | – | – | – | 5438918 | 5438918 |
| Balance, March 31, 2026 | 56732596 | $56733 | $36786545 | (990955) | $(2348392) | $20518529 | $55013415 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | **Treasury Stock** | **Treasury Stock** | | |
|  | **Shares** | **Amount** | **Additional <br> Paid-in**<br>**Capital** | **Shares** | **Amount** | **Retained**<br>**Earnings** | **Total Stockholders'**<br>**Equity** |
| Balance, December 31, 2024 | 54358382 | $54358 | $24632205 | (834708) | $(1772929) | $7527998 | $30441632 |
| &nbsp;&nbsp;&nbsp;Stock issued upon vesting of restricted stock | 724000 | 724 | (724) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation |  |  | 672318 |  |  |  | 672318 |
| &nbsp;&nbsp;&nbsp;Repurchase of common stock |  |  |  | (100000) | (375786) |  | (375786) |
| &nbsp;&nbsp;&nbsp;Issuance of stock in business combination |  |  | 5950000 |  |  |  | 5950000 |
| &nbsp;&nbsp;&nbsp;Net income | – | – | – | – | – | 2586100 | 2586100 |
| Balance, March 31, 2025 | 55082382 | $55082 | $31253799 | (934708) | $(2148715) | $10114098 | $39274264 |

---

See accompanying notes to unaudited condensed consolidated financial statements.

**PAYSIGN, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended <br> March 31,** | **Three Months Ended <br> March 31,** |
|  | **2026** | **2025** |
| Cash flows from operating activities: |  |  |
| Net income | $5438918 | $2586100 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 1284003 | 672318 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 2636156 | 1801003 |
| &nbsp;&nbsp;&nbsp;Noncash lease expense | 206765 | 109168 |
| &nbsp;&nbsp;&nbsp;Deferred income taxes, net | 57865 | 519717 |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts receivable | (22056599) | (19595520) |
| &nbsp;&nbsp;&nbsp;Other receivables | 581301 | 557348 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (1311832) | (131871) |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 17133274 | 14584756 |
| &nbsp;&nbsp;&nbsp;Operating lease liability | (105320) | (99567) |
| &nbsp;&nbsp;&nbsp;Customer card funding | 14921227 | (7036629) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) operating activities | 18785758 | (6033177) |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Purchase of fixed assets | (266465) | (78651) |
| &nbsp;&nbsp;&nbsp;Capitalization of internally developed software | (1408876) | (2354866) |
| &nbsp;&nbsp;&nbsp;Purchase of intangible assets | (400000) | (10338) |
| &nbsp;&nbsp;&nbsp;Net assets acquired in business combination | – | (2000000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (2075341) | (4443855) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Payments on other liability | (2000000) |  |
| &nbsp;&nbsp;&nbsp;Repurchase of common stock | (199677) | (375786) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (2199677) | (375786) |
| Net change in cash and restricted cash | 14510740 | (10852818) |
| Cash and restricted cash, beginning of period | 164984711 | 122343186 |
| Cash and restricted cash, end of period | $179495451 | $111490368 |
| Cash and restricted cash reconciliation: |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $20545119 | $6847021 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 158950332 | 104643347 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cash and restricted cash | $179495451 | $111490368 |
| Supplemental cash flow information: |  |  |
| &nbsp;&nbsp;&nbsp;Non-cash assets acquired in business combination | $– | $15758637 |
| &nbsp;&nbsp;&nbsp;Non-cash liabilities incurred in business combination | $– | $(9808637) |
| &nbsp;&nbsp;&nbsp;Common stock issued in business combination | $– | $(5950000) |
| &nbsp;&nbsp;&nbsp;Cash paid for taxes | $355 | $– |

---

See accompanying notes to unaudited condensed consolidated financial statements.

**PAYSIGN, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(UNAUDITED)**

1.&nbsp;&nbsp;&nbsp;&nbsp; <u>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT POLICIES</u>

The foregoing unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission ("SEC"). Accordingly, these financial statements do not include all the disclosures required by GAAP for complete financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2025. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.

The preparation of financial statements in accordance with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Company's financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions that could have a material effect on the reported amounts of the Company's financial position and results of operations.

Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026.

<u>About Paysign, Inc.</u>

Paysign, Inc. (the "Company," "Paysign," "we" or "our") was incorporated on August 24, 1995, and trades under the symbol PAYS on The Nasdaq Stock Market LLC. Paysign is a provider of prepaid card programs, comprehensive patient affordability offerings, life science software technology solutions, digital banking services and integrated payment processing designed for businesses, consumers and government entities. Headquartered in Nevada, the Company creates customized, innovative payment solutions for clients across all industries, including pharmaceutical, healthcare, hospitality and retail.

<u>Principles of Consolidation</u> – The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.

<u>Subsequent Events</u> – The Company discloses subsequent events that provide evidence about conditions that did not change the condensed consolidated financial statements at the balance sheet date but have a significant effect on the financial statements at the time of occurrence or on future operations of the Company. There have been no subsequent events since the balance sheet date.

Segment Reporting – The Company operates as one business, a vertically integrated provider of prepaid card products and processing services. The Company's chief operating decision maker ("CODM"), who is the Company's chief executive officer, utilizes a consolidated approach to assess the performance of and allocate resources to the business. Accordingly, management has concluded that the Company consists of a single operating segment and single reportable segment for accounting and financial reporting purposes.

The CODM regularly assesses the performance of the single operating and reporting segment based on consolidated net income. The CODM reviews expenses at a level consistent with those reported in the Company's consolidated statements of income. All significant expense categories are reflected in the consolidated statements of income. The measure of segment assets is reflected in the consolidated statements of financial condition as total assets.

<u>Use of Estimates</u> – The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and (iii) the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

<u>Cash and Cash Equivalents</u> – The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows. The Company had no cash equivalents at March 31, 2026 and December 31, 2025, respectively.

<u>Restricted Cash</u> – At March 31, 2026 and December 31, 2025, restricted cash consisted of funds held specifically for our card product and pharma patient affordability programs that are contractually restricted to use. The Company includes changes in restricted cash balances with cash and cash equivalents when reconciling the beginning and ending total amounts in our condensed consolidated statements of cash flows.

Reimbursement Receivables– At March 31, 2026 and December 31, 2025, accounts receivable included $79,255,866 and $62,366,232, respectively, of customer reimbursement balances of pass-through claims, which are fully offset in accounts payable and accrued liabilities. Accounts receivable also include accruals and trade receivables for program management and processing fees that have terms pursuant to their related contracts.

The Company applied current accounting guidance to evaluate whether its accounts receivable balances were subject to credit losses. A combination of aging and loss-rate methodologies was used to estimate current expected credit losses. In developing this estimate, the Company considered a broad range of information, including historical loss experience adjusted for current conditions and expectations of future trends. The evaluation also incorporated qualitative and quantitative risk factors such as the age of receivable balances, expected timing of payment, contract terms and conditions, geographic risk and relevant industry or economic trends. Based on this assessment, the Company concluded that any potential credit loss estimate and related allowance would be immaterial and, therefore, no allowance was recorded.

<u>Concentrations of Credit Risk</u> – Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash. The Company maintains its cash and cash equivalents and restricted cash in various bank accounts primarily with one financial institution in the United States, which at times may exceed federally insured limits. If this financial institution were to be placed into receivership, we may be unable to access the cash we have on deposit. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business could be adversely affected. The Company has not experienced any losses, nor does it anticipate any losses with respect to such accounts. At March 31, 2026 and December 31, 2025, the Company had approximately $3,495,517 and $1,427,627, respectively, in excess of federally insured bank account limits. In February of 2024, the Company initiated a program with one of our financial institutions called deposit swapping, where the financial institution utilizes a third-party who is participating in reciprocal deposit networks. This program is an alternative way for our financial institution to offer us full Federal Deposit Insurance Corporation ("FDIC") insurance on deposits over $250,000. Under this program, deposit networks divide uninsured deposits into smaller units and distribute these monies among participating banks in the network where the monies are fully FDIC insured.

As of March 31, 2026, the Company also had a concentration of accounts receivable risk, as two pharma patient affordability customers each individually represented 16% and 15% of our accounts receivable balance. One pharma patient affordability customer individually represented 31% of our accounts receivable balance on December 31, 2025. These accounts receivable balances relate to pass-through claim reimbursements that have been paid on behalf of the pharma program customers.

<u>Business Combinations</u> – The Company accounts for business combinations using the acquisition method. As of the acquisition date, the acquirer recognizes, separately from goodwill, the identifiable assets acquired, the liabilities assumed and any non-controlling interest in the acquiree. Goodwill is initially measured at cost, being the excess of the cost of acquisition over the fair value of the net identifiable assets acquired and liabilities assumed. The cost of an acquisition is measured as the aggregate of the consideration transferred, measured at acquisition date fair value and the amount of any non-controlling interest in the acquiree. If the cost of acquisition is lower than the fair value of the net identifiable assets, the difference is recognized in profit. Acquisition costs are expensed as incurred.

<u>Fixed Assets</u> – Fixed assets are stated at cost less accumulated depreciation. Depreciation is principally recorded using the straight-line method over the estimated useful life of the asset, which is generally 3 to 10 years. The cost of repairs and maintenance is charged to expense as incurred. Leasehold improvements are capitalized and depreciated over the shorter of the remaining lease term or the estimated useful life of the improvements. Expenditures for property betterments and renewals are capitalized. Upon the sale or other disposition of a depreciable asset, cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in other income (expense).

The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of fixed assets or whether the remaining balance of fixed assets should be evaluated for possible impairment. The Company uses an estimate of the related undiscounted cash flows over the remaining life of the fixed assets in measuring their recoverability.

<u>Intangible Assets</u> – For intangible assets, the Company recognizes an impairment loss if the carrying amount of the intangible asset is not recoverable and exceeds its fair value. The carrying amount of the intangible asset is considered not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use of the asset.

Intangible assets with an indefinite-life are not amortized. Intangible assets with a finite life are amortized on a straight-line basis over their estimated useful lives, which are generally 3 to 30 years.

 

*Goodwill* – Our methodology for allocating the purchase price relating to purchase acquisitions is determined through established valuation techniques. Goodwill represents a residual value as of the acquisition date, which in most cases results in measuring goodwill as an excess of the purchase consideration transferred plus the fair value of any noncontrolling interest in the acquired company over the fair value of net assets acquired, including contingent consideration. We perform goodwill impairment tests on an annual basis, evaluated at a single reporting unit in the fourth fiscal quarter and between annual tests in certain circumstances. The assessment of fair value for goodwill and purchased intangible assets is based on factors that market participants would use in an orderly transaction in accordance with the new accounting guidance for the fair value measurement of non-financial assets.

As of March 31, 2026 and December 31, 2025, goodwill recorded in the condensed consolidated balance sheets totaled $4,487,637, reflecting no change during the three months ended March 31, 2026. This goodwill arose from the Company's acquisition of Gamma Innovation LLC on March 19, 2025 (see Note 2 – ACQUISITION" in the notes to the accompanying condensed consolidated financial statements). The fair value of the Company's reporting unit is estimated using assumptions based on operating results, market conditions, industry trends, and other relevant factors. Changes in these estimates and assumptions could materially affect the determination of fair value and the assessment of goodwill impairment. For the three months ended March 31, 2026, management performed a qualitative assessment and concluded that it is more likely than not that goodwill was not impaired.

*Internally Developed Software Costs –* Computer software development costs are generally expensed as incurred. However, costs related to software developed for internal use, for resale, or for website development may be capitalized when they meet the criteria outlined below. These costs include compensation and related expenses, hardware and software costs and expenditures incurred in developing features and functionality.

For computer software developed or obtained for internal use, costs that are incurred in the preliminary project and post implementation stages of software development are expensed as incurred. Costs incurred during the application and development stage are capitalized. Capitalized costs are amortized using the straight-line method over a three-year estimated useful life, beginning in the period in which the software is available for use.

Costs incurred to develop software products for sale, lease or other marketing are expensed as incurred until technological feasibility is established. Once technological feasibility has been established, qualifying development costs are capitalized until the product is available for general release to customers. Capitalized costs are amortized using the straight-line method over a 10-year estimated useful life.

*Contract Assets* – Incremental costs to obtain or fulfill a contract with a customer are capitalized. The Company determines the costs that are incremental by confirming the costs (i) are directly related to a customer's contract, (ii) generate or enhance resources to fulfill contract performance obligations in the future, and (iii) are recoverable. Amortization is on a straight-line basis generally over three to five years, beginning when goods and services are transferred to the customer or group of customers.

*Hosting Implementation –* Costs to implement the cloud computing arrangements (the "hosting site") are accounted for by following the same model as internally developed software costs. Costs that are incurred in the preliminary project and post implementation stages of hosting development are expensed when they are incurred. Costs incurred during the application and development stage are capitalized. Capitalized costs are amortized using the straight-line method over a three-year estimated useful life, beginning in the period when the hosting site is available for use.

<u>Customer Card Funding</u> – As of March 31, 2026 and December 31, 2025, customer card funding represents funds loaded or available to be loaded on cards for the Company's card product programs, or funds available to cover reimbursement claims for the Company's pharma patient affordability programs.

Fair Value of Financial Instruments– Under applicable accounting guidance, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The Company determines the fair values of our financial instruments based on the fair value hierarchy established under applicable accounting guidance which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following describes the three-level hierarchy:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include debt and equity securities. We currently do not have any assets or liabilities in this category.

Level 2 – Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. We currently do not have any assets or liabilities in this category.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the overall fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments for which the determination of fair value requires significant management judgment or estimation. The fair value for such assets and liabilities is generally determined using pricing models, market comparables, discounted cash flow methodologies or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability. During the three months ended March 31, 2026, there were no changes in the fair value of assets and liabilities within this category.

<u>Earnings Per Share</u> – Basic earnings per share exclude any dilutive effects of options, warrants and convertible securities. Basic earnings per share is computed using the weighted-average number of common shares outstanding during the applicable period. Diluted earnings per share is computed using the weighted-average number of common and common stock equivalent shares outstanding during the period using the treasury stock method. Common stock equivalent shares are excluded from the computation if their effect on the diluted earnings per share calculation is anti-dilutive.

<u>Revenue and Expense Recognition</u> – In determining when and how revenue is recognized from contracts with customers, the Company performs the following five-step analysis: (i) identification of contracts with customers; (ii) determination of performance obligations; (iii) measurement of the transaction price; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company generates revenues from plasma card programs through fees generated from cardholder fees and interchange fees. Revenues from pharma programs are generated through card program management fees, transaction claims processing fees, interchange fees, customer support fees and other billable services. Other revenues are generated through cardholder fees, interchange fees, program management fees, load fees, settlement income and breakage. Life science software technology solutions, acquired through our Gamma Innovation LLC acquisition, has not generated revenue as of March 31, 2026.

Plasma and pharma program revenues include both fixed and variable components. Cardholder fees represent an obligation to the cardholder based on a per transaction basis and are recognized at a point in time when the performance obligation is fulfilled. Card program management fees and transaction claims processing fees include an obligation to our program sponsors and are generally recognized when earned on a monthly basis and are typically due pursuant to the contract terms. The Company uses the output method to recognize card program management fee revenue at the amount of consideration to which an entity has a right to invoice. The performance obligation is satisfied when the services are transferred to the customer which the Company determined to be monthly, as the customer simultaneously receives and consumes the benefit from the Company's performance. Interchange fees are earned when customer-issued cards are processed through card payment networks as the nature of our promise to the customer is that we stand ready to process transactions at the customer's requests on a daily basis over the contract term. Since the timing and quantity of transactions to be processed by us are not determinable, we view interchange fees to comprise an obligation to stand ready to process as many transactions as the customer requests. Accordingly, the promise to stand ready is accounted for as a single series performance obligation. The Company uses the right to invoice practical expedient and recognizes interchange fee revenue concurrent with the processing of card transactions. Interchange fees are settled in accordance with the card payment network terms and conditions, which is typically within a few days.

The portion of the dollar value of prepaid-stored value cards that consumers do not ultimately redeem are referred to as breakage. In certain card programs where we hold the cardholder funds and expect to be entitled to a breakage amount, we recognize revenue using estimated breakage rates ratably over the estimated card life; provided that a significant reversal of the amount of breakage revenue recognized is not probable, and record adjustments to such estimates when redemption is remote or we are legally defeased of the obligation, if applicable. For each program, we utilize a third party to estimate breakage rates based on historical redemption patterns, market-specific trends, escheatment rules and existing economic conditions. The Company accounts for breakage in accordance with Accounting Standards Update ("ASU") 2016-04, *Liabilities—Extinguishment of Liabilities (Subtopic 405-20): Recognition of Breakage for Certain Prepaid Stored-Value Cards* for the recognition of such revenue. Breakage revenue is recorded in other revenue on the condensed consolidated statements of operations and was $112,046 and $101,190 for the three months ended March 31, 2026 and 2025, respectively.

The Company utilizes the remote method of revenue recognition for settlement income whereby the unspent card balances will be recognized as revenue at the expiration of the cards or the respective card program. The Company records all revenue on a gross basis since it is the primary obligor and establishes the price in the contract arrangement with its customers. The Company is currently under no obligation to refund any fees, and the Company does not currently have any obligations for disputed claim settlements. Given the nature of the Company's services and contracts, generally it has no contract assets as it pertains to services rendered but not invoiced. Settlement income was $0 for the three months ended March 31, 2026 and December 31, 2025, respectively.

Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, customer service, program management, application integration setup, fraud charges and sales and commission expense.

<u>Operating Leases</u> – The Company determines if a contract is or contains a leasing element at contract inception or the date in which a modification of an existing contract occurs. In order for a contract to be considered a lease, the contract must transfer the right to control the use of an identified asset for a period of time in exchange for consideration. Control is determined to have occurred if the lessee has the right to (i) obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use and (ii) direct the use of the identified asset.

In determining the present value of lease payments at lease commencement date, the Company utilizes its incremental borrowing rate based on the information available, unless the rate implicit in the lease is readily determinable. Certain lease contracts include obligations to pay for other services, such as maintenance, We account for these other services as a non-lease component of the lease and they are not considered when accounting for the lease. The liability for operating leases is based on the present value of future lease payments. Operating lease expenses are recorded as rent expense, which is included within selling, general and administrative expenses within the condensed consolidated statements of operations and presented as operating cash outflows within the condensed consolidated statements of cash flows.

 

Leases with an initial term of 12 months or less are not recorded on the balance sheet, with lease expense for these leases recognized on a straight-line basis over the lease term.

<u>Stock-Based Compensation</u> – The Company recognizes compensation expense for all restricted stock awards and stock options. The fair value of restricted stock awards is measured using the grant date trading price of our stock. The fair value of stock options is estimated at the grant date using the Black-Scholes option-pricing model, and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. We have elected to recognize compensation expense for all options with graded vesting on a straight-line basis over the vesting period of the entire option. The determination of fair value using the Black-Scholes pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility and the risk-free interest rate.

<u>Recently Adopted Accounting Pronouncement</u> – In December 2023, the Financial Accounting Standards ("FASB") issued Accounting Standards Update ("ASU") 2023-09, "*Income Taxes – Improvements to Income Tax Disclosures*", requiring enhancements and further transparency to certain income tax disclosures, most notably the tax rate reconciliation and income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024 on a prospective basis and retrospective application is permitted. We adopted ASU 2023-09 effective December 31, 2025 and applied it retrospectively to all periods presented in the financial statements. The adoption resulted in expanded disclosures of the components of the reconciliation between income tax expense and statutory expectations as well as expanded disclosures of income taxes paid. See "Note 10—INCOME TAX" for further information. Because the ASU affects disclosures only, the adoption did not affect the company's consolidated statements of operations or consolidated balance sheets.

Recently Issued Accounting Pronouncement Not Yet Adopted – In November 2024, the FASB issued ASU 2024-03, "*Disaggregation of Income Statement Expenses*," which requires disclosure in the notes to financial statements of specified information about certain costs and expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. The amendments should be applied either prospectively to the financial statements issued for reporting periods after the effective date of this update or retrospectively to any or all prior periods presented in the financial statements. We are currently evaluating the potential effects of ASU 2024-03 on our consolidated financial statements and related disclosures.

In July 2025, the FASB issued ASU 2025-05, "*Financial Instruments — Credit Losses – Measurement of Credit Losses for Accounts Receivable and Contract Assets*", which provides a practical expedient for estimating expected credit losses for current accounts receivable and current contract assets. ASU 2025-05 will be effective for annual periods beginning after December 15, 2025, and interim periods within those annual reporting periods and should be applied prospectively. The Company is currently evaluating the impact that this guidance will have on the Company's consolidated financial statements and related disclosures.

In September 2025, the FASB issued ASU 2025-06, "*Targeted Improvements to the Accounting for Internal-Use Software*," which simplifies the capitalization guidance by removing all references to software development project stages, so that the guidance is neutral to different software development methods. The amendments in this update are effective for annual periods beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either retrospectively or prospectively to software costs incurred after the adoption date or on a modified prospective basis. We are currently evaluating the potential effects of ASU 2025-06 on our consolidated financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-11, "*Interim Reporting –Narrow-Scope Improvements*". The amendments are intended to improve the clarity and navigability of interim reporting requirements within Topic 270 by clarifying when interim reporting guidance applies, enhancing the organization of required interim disclosures and specifying the form and content of interim financial statements. The guidance responds to stakeholder feedback that existing interim reporting requirements were difficult to navigate because of the historical origins and accumulated amendments within Topic 270. ASU 2025-11 adds a disclosure principle requiring entities to disclose events that occur after the end of the most recent annual reporting period that have a material impact on the entity. The amendments also introduce a comprehensive list of required interim disclosures drawn from various codification topics and clarify the presentation requirements for interim financial statements, including condensed financial statements and accompanying footnotes. Importantly, the ASU does not change the fundamental nature of interim reporting nor expand or reduce existing disclosure requirements; rather, it improves clarity and consistency across entities that issue interim financial statements in accordance with GAAP. ASU 2025-11 is effective for the Company for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 and does not expect the adoption to have a material effect on its consolidated financial statements.

2.&nbsp;&nbsp;&nbsp;&nbsp; <u>ACQUISITION</u>

On March 19, 2025, we entered into an Asset Purchase Agreement (the "Asset Purchase Agreement") with Gamma Innovation LLC, a Pennsylvania limited liability company ("Gamma"), Beta Software and Technologies LLC, a Delaware limited liability company, and Michael Ngo, an individual, pursuant to which we acquired substantially all the assets of Gamma. Gamma is a software and services company focusing on the blood and plasma collection industry that developed innovative solutions targeting donor engagement, retention and management. The Gamma acquisition aligns with our technology and market presence by offering additional engagement, compensation and resource management solutions across our core markets. The new technologies acquired consist of the following solutions: (i) a donor engagement application designed to reduce plasma labor costs and donor fees while improving donor retention; (ii) a customer resource management platform designed to reduce unnecessary expenses and improve donor engagement, marketing effectiveness and retention; and (iii) a donor management solution designed to improve plasma donation center efficiency by reducing operational costs and optimizing donor compensation.

Total purchase consideration transferred or transferable was $15,558,637, which consisted of the following:

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;Cash paid upfront (1) | $2000000 |
| &nbsp;&nbsp;&nbsp;Present value of future cash paid (1) | 6618637 |
| &nbsp;&nbsp;&nbsp;Equity consideration (2) | 5950000 |
| &nbsp;&nbsp;&nbsp;Earn-out contingent consideration (3) | 990000 |
| Total consideration | $15558637 |

---

(1) Pursuant to the Asset Purchase Agreement the cash purchase price paid was $10,000,000 to be paid in five equal tranches with the initial payment made on March 19, 2025 and four subsequent payments to be made on each subsequent annual anniversary of the initial payment. The fair value of this consideration was estimated based on the present value of the future payments. The average discount rate of 8% was based on the Company's estimated cost of debt. The present value of future payments is recorded in other liabilities on the condensed consolidated balance sheets.

(2) Pursuant to the Asset Purchase Agreement the stock consideration paid was 2,500,000 shares of restricted common stock that vest in five equal amounts beginning on March 31, 2025 and annually thereafter for the next four years. Fair value was estimated using the Company's stock price of $2.38 on the valuation date. The stock consideration is recorded in the condensed consolidated statements of stockholders' equity.

(3) Pursuant to the Asset Purchase Agreement an additional earn-out stock consideration of 500,000 shares of our common stock, up to a total consideration of 2,500,000 shares of our common stock, may be paid upon the achievement of certain gross revenue performance targets for each trailing 12-month period beginning on March 20, 2026 and ending on March 19, 2030. The contingent payable is recorded in other liabilities on the condensed consolidated balance sheets.

The Company's contingent consideration liability is measured at fair value on a recurring basis and is classified within Level 3 of the fair value hierarchy. Changes in fair value of contingent consideration are recorded in the consolidated statements of operations. The fair value is estimated using the Monte Carlo simulation model based on projected revenues and expected payout scenarios. Significant unobservable inputs include forecasted revenues, probability of achieving performance targets and a risk-free discount rate of 4%. There were no significant changes in the valuation techniques or inputs used in the measurement during the three months ended March 31, 2026. Accordingly, the Company has not presented a reconciliation of the beginning and ending balances of the Level 3 fair value measurement. Fair value adjustments to the contingent consideration liability was $0 for the three months ended March 31, 2026.

We have accounted for the Gamma acquisition as a business combination, which generally requires that we recognize the assets acquired and liabilities assumed at fair value as of the acquisition date. The final estimated acquisition date fair values of major classes of assets acquired and liabilities assumed, including a reconciliation to the total final purchase consideration, were as follows:

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;Identifiable intangible assets | $11071000 |
| Total identifiable net assets | 11071000 |
| &nbsp;&nbsp;&nbsp;Goodwill | 4487637 |
| Total assets acquired | $15558637 |

---

During the second quarter of 2025, a measurement period adjustment of $2,200,000 related to the Gamma acquisition decreased the amount of earn-out contingent consideration from $3,190,000 to $990,000, which decreased the amounts attributable to acquired technology and goodwill. The updated amounts are reflected in the above purchase consideration and value of goodwill and identifiable intangible assets.

Goodwill arising from the acquisition was attributable to expected growth opportunities of the acquired technology, potential synergies from combining the acquired business into our existing business, and an assembled workforce. We expect that approximately $4,487,637 of the goodwill from this acquisition will be deductible for income tax purposes.

The estimated fair value includes $10,568,000 of acquired technologies and identifiable intangible assets, all of which have finite lives. The fair value of the identifiable intangible assets has been estimated using the income approach by using the multi-period excess earnings method. Under this method, an intangible asset's fair value is equal to the present value of future economic benefits to be derived from ownership of the asset. The estimated fair value was developed by discounting future net cash flows to their present value at market-based rates of return. Such assumptions included forecasted revenues, cost of sales and operating expenses, technology obsolescence and weighted average cost of capital. The Company also utilized the cost replacement approach for certain immaterial intangible assets included within the acquired technology stack. The determination of the useful lives for acquired technologies is based upon various industry studies, historical acquisition experience and economic factors. The following table reflects the final estimated acquisition date fair values of the identified intangible assets of Gamma and their respective weighted-average estimated amortization periods:

---

| | | |
|:---|:---|:---|
|  | **Estimated Fair Value** | **Weighted Avg. Estimated Amortization (years)** |
| Non-compete agreement | $503000 | 9 |
| Acquired technologies | 10568000 | 10 |
| Total identifiable intangible assets | $11071000 |  |

---

During the fourth quarter of 2025, we revised the weighted-average useful life of acquired technology, reducing its amortization period from 15 years to 10 years. The updated amortization periods are reflected in the acquisition date fair values of identifiable intangible assets and their respective useful lives.

The historical revenue and earnings of Gamma were not material for the purpose of presenting pro forma information. For the three months ended March 31, 2026 and 2025, transaction costs in the amount of $0 and $108 thousand, respectively associated with this business combination have been expensed as incurred and are recorded in selling, general & administration expense on the condensed consolidated statements of operation.

3.&nbsp;&nbsp;&nbsp;&nbsp; <u>FIXED ASSETS, NET</u>

Fixed assets consist of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31, <br> 2026** | **December 31, <br> 2025** |
| Equipment | $2866927 | $2830319 |
| Software | 640407 | 636582 |
| Furniture and fixtures | 858708 | 858708 |
| Website costs | 69881 | 69881 |
| Leasehold improvements | 993276 | 767244 |
|  | 5429199 | 5162734 |
| Less: accumulated depreciation | (3421806) | (3264842) |
| Fixed assets, net | $2007393 | $1897892 |

---

Depreciation expense for the three months ended March 31, 2026 and 2025 was $156,964 and $101,847, respectively.

4.&nbsp;&nbsp;&nbsp;&nbsp; <u>INTANGIBLE ASSETS, NET</u>

Intangible assets consist of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br> **2026** | **December 31, <br> 2025** |
| Patents and trademarks | $38186 | $38186 |
| Platform | 37527956 | 36119080 |
| Customer lists and contracts | 1177200 | 1177200 |
| Licenses | 637576 | 237576 |
| Hosting implementation | 43400 | 43400 |
| Contract assets | 340327 | 340326 |
| Non-compete agreement | 503000 | 503000 |
| Acquired technologies | 10568000 | 10568000 |
|  | 50835645 | 49026768 |
| Less: accumulated amortization | (29159747) | (26680555) |
| Intangible assets, net | $21675898 | $22346213 |

---

Intangible assets are amortized over their useful lives ranging from periods of 3 to 30 years. Amortization expense for the three months ended March 31, 2026 and 2025 was $2,479,192 and $1,699,156, respectively.

5.&nbsp;&nbsp;&nbsp;&nbsp; <u>LEASE</u>

The Company entered into an operating lease for office space which became effective in June 2020. The lease term is 10 years from the effective date and allows for two optional extensions of five years each. The two optional extensions are not recognized as part of the right-of-use asset or lease liability since it is not reasonably certain that the Company will extend this lease. As of March 31, 2026, the remaining lease term was 4.2 years and the discount rate used was 6%.

The Company entered into an operating lease for additional office space which became effective in September 2025. The lease term is 7.4 years from the effective date and allows for two optional extensions of five years each. The two optional extensions are not recognized as part of the right-of-use asset or lease liability since it is not reasonably certain that the Company will extend this lease. As of March 31, 2026, the remaining lease term was 6.8 years and the discount rate used was 8%.

Operating lease cost included in selling, general and administrative expenses was $365,060 and $189,425 for the three months ended March 31, 2026 and 2025, respectively, which include common area maintenance expenses of $75,507 and $36,832, respectively. Cash paid for the operating lease was $211,131 and $142,992 for the three months ended March 31, 2026 and 2025, respectively.

The following is the lease maturity analysis of our operating leases as of March 31, 2026:

---

| | |
|:---|:---|
| Year ending December 31, |  |
| &nbsp;&nbsp;&nbsp;2026 (excluding the three months ended March 31, 2026) | $945387 |
| &nbsp;&nbsp;&nbsp;2027 | 1277013 |
| &nbsp;&nbsp;&nbsp;2028 | 1296105 |
| &nbsp;&nbsp;&nbsp;2029 | 1315770 |
| &nbsp;&nbsp;&nbsp;2030 | 962340 |
| Thereafter | 1516756 |
| Total lease payments | 7313371 |
| Less: Imputed interest | (1393297) |
| Present value of future lease payments | 5920074 |
| Less: current portion of lease liability | (871495) |
| Long-term portion of lease liability | $5048579 |

---

6.&nbsp;&nbsp;&nbsp;&nbsp; <u>CUSTOMER CARD FUNDING LIABILITY</u>

The Company issues prepaid cards with various provisions for cardholder fees or expiration. Revenue generated from cardholder transactions and interchange fees are recognized when the Company's performance obligation is fulfilled. Unspent balances left on prepaid cards are recognized as settlement income at the expiration of the cards and the card program. Contract liabilities related to prepaid cards represent funds on cards and client funds held to be loaded to a card before the amounts are ultimately spent by the cardholders or recognized as revenue by the Company. Contract liabilities related to prepaid cards are included in customer card funding liability on the condensed consolidated balance sheet.

The opening and closing balances of the Company's liabilities are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Beginning balance | $143191068 | $111328270 |
| Increase (decrease), net | 14921227 | (7036629) |
| Ending balance | $158112295 | $104291641 |

---

The amount of revenue recognized during the three months ended March 31, 2026 and 2025 that was included in the opening contract liability for prepaid cards was $3,463,162 and $2,727,566, respectively.

7.&nbsp;&nbsp;&nbsp;&nbsp; <u>COMMON STOCK</u>

At March 31, 2026, the Company's authorized capital stock was 150,000,000 shares of common stock, par value $0.001 per share, and 25,000,000 shares of preferred stock, par value $0.001 per share. On that date, the Company had 56,732,596 shares of common stock issued and 55,741,641 shares of common stock outstanding. There were no shares of preferred stock outstanding.

Stock-based compensation expense related to Company grants for the three months ended March 31, 2026 and 2025 was $1,284,003 and $672,318, respectively, and is included in selling, general and administrative expense.

<u>2026 Transactions</u> – During the three months ended March 31, 2026, the Company issued 711,000 shares of common stock for vested stock awards. The Company did not receive proceeds for the exercise of stock options during the three months ended March 31, 2026.

During the three months ended March 31, 2026, the Company did not grant restricted stock awards.

<u>2025 Transactions</u> – During the three months ended March 31, 2025, the Company issued 724,000 shares of common stock for vested stock awards and the exercise of stock options. No stock options were exercised.

The Company also granted 3,025,000 restricted stock awards during the three months ended March 31, 2025. For the stock awards granted, the weighted average grant date fair value was $2.38 and vest over a period of one to five years.

8. &nbsp;&nbsp;&nbsp;&nbsp;<u>BASIC AND FULLY DILUTED NET INCOME (LOSS) PER COMMON SHARE</u>

The following table sets forth the computation of basic and fully diluted net income per common share for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
|  | **2026** | **2025** |
| Numerator: |  |  |
| Net income | $5438918 | $2586100 |
| Denominator: |  |  |
| &nbsp;&nbsp;&nbsp;Weighted average common shares: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Denominator for basic calculation | 55167911 | 53576030 |
| &nbsp;&nbsp;&nbsp;Weighted average effects of potentially diluted common stock: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock options (calculated using the treasury method) | 985840 | 694077 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unvested restricted stock grants | 4868309 | 872404 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Denominator for fully diluted calculation | 61022060 | 55142511 |
| Net income per common share: |  |  |
| &nbsp;&nbsp;&nbsp;Basic | $0.10 | $0.05 |
| &nbsp;&nbsp;&nbsp;Fully diluted | $0.09 | $0.05 |
| Anti-dilutive shares: |  |  |
| &nbsp;&nbsp;&nbsp;Stock options |  |  |
| &nbsp;&nbsp;&nbsp;Unvested restricted stock options |  |  |

---

9.&nbsp;&nbsp;&nbsp;&nbsp;<u>COMMITMENTS AND CONTINGENCIES</u>

<u>Pending or Threatened Litigation</u> – From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not currently a party to any pending or threatened legal proceedings that we believe could have a material adverse effect on our business or financial condition.

10. <u>INCOME TAX</u>

The following table summarizes the Company's income tax expense and effective tax rates for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  | **2026** | **2025** |
| Income before income taxes | $7468998 | $3251264 |
| Income tax expense | $2030080 | $665164 |
| Effective tax rate | 27.2% | 20.5% |

---

The effective tax rates for the three months ended March 31, 2026 and 2025 were based on the Company's forecasted annualized effective tax rates for federal, state and local income taxes and were adjusted for discrete items that occurred within the periods presented. The effective tax rate for the three months ended March 31, 2026 varies from the three months ended March 31, 2025 primarily as a result of an increase in discrete items, offset by tax benefits related to our stock-based compensation.

Under the provisions of the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") signed into law in 2020 and the subsequent extension of the CARES Act through September 30, 2021, the Company was eligible for a refundable employee retention credit subject to certain criteria. The Company has elected an accounting policy to recognize government assistance when it is probable that the Company is eligible to receive the assistance and present the credit as a reduction of the related expense. As of March 31, 2026 and December 31, 2025, the Company recorded $345,228 in other receivables on the condensed consolidated balance sheet related to U.S. Federal Government refunds.

**ITem 2. Management's discussion and analysis of financial condition and results of operations.**

***Disclosure Regarding Forward-Looking Statements***

 ****

This Quarterly Report on Form 10-Q includes forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") ("Forward-Looking Statements"). All statements other than statements of historical fact included in this report are Forward-Looking Statements. These Forward-Looking Statements are based on our current expectations, assumptions, estimates and projections about our business and our industry. Words such as "believe," "anticipate," "expect," "intend," "plan," "propose," "may," and other similar expressions identify Forward-Looking Statements. Specific forward-looking statements made herein include: our belief that we do not anticipate any losses with respect to accounts with balances exceeding federally insured limits; our expected lease obligations for subsequent years; our belief that our platform can be seamlessly integrated with our clients' systems; our belief that changes in the estimates used to calculate the fair value of our business from year to year could materially affect the determination of fair value; our conclusion that goodwill impairment for the three months ended March 31, 2026 was more likely than not impaired; our belief that our distinctive positioning allows us to provide end-to end technologies that securely manage transaction processing, cardholder enrollment, value loading, account management, data and analytics, and customer service; our belief that our architecture is known for its cross-platform compatibility, flexibility, and scalability - allowing our clients and partners to leverage these advantages for cost savings and revenue opportunities; our expectation that the adoption of ASU 2025-11 will not have a material effect on our consolidated financial statements; our focus of our marketing efforts on corporate incentive and expense prepaid card products in various market verticals, including but not limited to, general corporate expense, healthcare related markets including patient affordability solutions, clinical trials and donor compensation, loyalty rewards and incentive cards; our plan for 2026 to continue to invest additional funds in technology improvements, sales and marketing, cybersecurity, fraud, customer service, and regulatory compliance; if a certain financial institution were to be placed into receivership, we may be unable to access the cash we have on deposit and if we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business could be adversely affected; our belief that from time to time we evaluate raising capital to enable us to diversify into new market verticals; our belief that if we do not raise new capital, that we will still be able to support our existing business and expand into new vertical markets using internally generated funds; our belief that the following measures are the primary indicators of our quarterly and annual revenues: gross dollar volume loaded on cards and conversion rates on gross dollar volume loaded on cards; our belief that the following are also key performance indicators: revenues, gross profit, operational expenses as a percentage of revenues, and cardholder participation; our belief that our available cash on hand, excluding restricted cash, along with our forecast for revenues and cash flows for the remainder of 2026 and through the first quarter of 2028, will be sufficient to sustain our operations for the next twenty-four months; we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business and an adverse result in these or other matters may arise from time to time that may harm our business; third-party software may be used for highly specialized business functions, which we may not be able to develop internally within time and budget constraints; and our expectation that the stock repurchase program will be completed within 36 months from the commencement date. In the normal course of our business, we, in an effort to help keep our stockholders and the public informed about our operations, may from time-to-time issue certain statements, either in writing or orally, that contain, or may contain, forward-looking statements. Although we believe that the expectations reflected in such Forward-Looking Statements are reasonable, we can give no assurance that such expectations will prove to have been correct. In addition, any statements that refer to expectations, projections, estimates, forecasts, or other characterizations of future events or circumstances are Forward-Looking Statements. These Forward-Looking Statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the Forward-Looking Statements. Such important factors ("Important Factors") and other factors are disclosed under "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 and in other reports filed with the Securities and Exchange Commission (the "SEC") from time to time. All prior and subsequent written and oral Forward-Looking Statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the Important Factors described below that could cause actual results to differ materially from our expectations as set forth in any Forward-Looking Statement made by or on behalf of us. You are cautioned not to place undue reliance on these Forward-Looking Statements, which relate only to events as of the date on which the statements are made. We undertake no obligation to publicly revise these Forward-Looking Statements to reflect events or circumstances that arise after the date hereof. You should refer to and carefully review the information in future documents we file with the SEC.

***Overview***

 ****

Paysign, Inc. (the "Company," "Paysign," "we" or "our"), headquartered in Nevada, was incorporated on August 24, 1995, and trades under the symbol PAYS on The Nasdaq Stock Market LLC. We are a vertically integrated provider of prepaid card products and processing services for corporate, consumer and government entities. Our payment solutions are utilized by our corporate customers as a means to increase customer loyalty, increase patient adherence rates, reduce administration costs and streamline operations. Public sector organizations can utilize our payment solutions to disburse public benefits or for internal payments. We market our prepaid card solutions under our Paysign® brand. As we are a payment processor and prepaid card program manager, we derive our revenue from all stages of the prepaid card lifecycle.

In addition to our payment solutions, we also offer life science technology solutions targeting blood and plasma collection organizations. These software solutions are marketed under the Apherion™ brand, and we derive our revenue from licensing, hosting and consulting fees.

We operate on a powerful, high-availability payment solutions platform with cutting-edge fintech capabilities that can be seamlessly integrated with our clients' systems. This distinctive positioning allows us to provide end-to-end technologies that securely manage transaction processing, cardholder enrollment, value loading, account management, data and analytics and customer service. Our architecture is known for its cross-platform compatibility, flexibility, and scalability – allowing our clients and partners to leverage these advantages for cost savings and revenue opportunities.

Our suite of product offerings includes solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, demand deposit accounts accessible with a debit card and software solutions targeting blood and plasma collection organizations. Our cards are sponsored by our issuing bank partners.

Our revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, breakage and settlement income. Revenue from cardholder fees, interchange, card program management fees and transaction claims processing fees is recorded when the performance obligation is fulfilled. Breakage is recorded ratably over the estimated card life based on historical redemption patterns, market-specific trends, escheatment rules, and existing economic conditions and relates solely to our open-loop gift card business which began at the end of 2022 and is recorded under other revenue on the condensed consolidated statements of operations. Settlement income is recorded at the expiration of the card or card program and relates primarily to our corporate incentive programs which is also recorded under other revenue on the condensed consolidated statements of operations.

The industry generally has two categories for our prepaid debit cards: (1) corporate and consumer reloadable cards and (2) non-reloadable cards.

Reloadable Cards: These types of cards are generally classified as payroll or considered general purpose reloadable ("GPR") cards. Payroll cards are issued by an employer to an employee in order to allow the employee to access payroll amounts that are deposited into an account linked to their card. GPR cards can also be issued to a consumer at a retail location or mailed to a consumer after completing an on-line application. GPR cards can be reloaded multiple times with a consumer's payroll, government benefit, a federal or state tax refund or through cash reload networks located at retail locations. Reloadable cards are generally open-loop cards as described below.

Non-Reloadable Cards: These are generally one-time use cards that are only active until the funds initially loaded to the card are spent. These types of cards are generally used as gift or incentive cards. Typically, these types of cards are used for the purchase of goods or services at retail locations and cannot be used to receive cash.

Both reloadable and non-reloadable cards may be open-loop, closed-loop or restricted-loop. Open-loop cards can be used to receive cash at ATM locations by PIN; or purchase goods or services by PIN or signature at retail locations virtually anywhere that the network brand (American Express, Discover, Mastercard, Visa, etc.) is accepted. Closed-loop cards can only be used at a specific merchant. Restricted-loop cards can be used at several merchants, or a defined group of merchants, such as all merchants at a specific shopping mall.

The prepaid card market in the United States has experienced significant growth in recent years due to consumers and merchants embracing improved technology, greater convenience, more product choices and greater flexibility. Prepaid cards have also proven to be an attractive alternative to traditional bank accounts for certain segments of the population, particularly those without, or who could not qualify for, a checking or savings account.

We manage all aspects of the prepaid card lifecycle, from managing the card design and approval processes with partners and networks, to production, packaging, distribution and personalization. We also oversee inventory and security controls, renewals, lost and stolen card management and replacement. We employ a 24/7/365 fully staffed, in-house customer service department which utilizes bilingual customer service representatives, Interactive Voice Response, and two-way short message service messaging and text alerts.

Currently, we are focusing our marketing efforts on corporate incentive and expense prepaid card products in various market verticals including but not limited to general corporate expense, healthcare related markets including patient affordability solutions, clinical trials and donor compensation, loyalty rewards and incentive cards.

As part of our continuing platform expansion process, we evaluate current and emerging technologies for applicability to our existing and future software platform. To this end, we engage with various hardware and software vendors in evaluation of various infrastructure components. Where appropriate, we use third-party technology components in the development of our software applications and service offerings. Third-party software may be used for highly specialized business functions, which we may not be able to develop internally within time and budget constraints. Our principal target markets for processing services include prepaid card issuers, retail and private-label issuers, small third-party processors and small and mid-size financial institutions in the United States and Mexico.

We have devoted more extensive resources to sales and marketing activities as we have added essential personnel to our marketing, sales and support teams. We market our Paysign payment solutions through direct marketing by the Company's sales team. Our primary market focus is on companies that require a streamlined payment solution for rewards, rebates, payment assistance, and other payments to their customers, employees, agents and others. To reach these markets, we focus our sales efforts on direct contact with our target market and attendance at various industry-specific conferences. We may, at times, utilize independent contractors who make direct sales and are paid commissions and/or restricted stock awards. We market our Paysign premier product through existing communication channels to a targeted segment of our existing cardholders, as well as to a broad group of individuals, ranging from non-banked to fully banked consumers with a focus on long term users of our product.

During the remainder of 2026, we plan to continue to invest additional funds in technology improvements, sales and marketing, cybersecurity, fraud, customer service and regulatory compliance. From time to time, we evaluate raising capital to enable us to diversify into new market verticals. If we do not raise new capital, we believe that we will still be able to support our existing business and expand into new vertical markets using internally generated funds.

***Results of Operations***

*Comparison of the Three Months Ended March 31, 2026 to the Three Months Ended March 31, 2025* 

 

The following table summarizes our condensed consolidated financial results for the three months ended March 31, 2026 in comparison to the three months ended March 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2026,**<br> **(Unaudited)** | **Three Months Ended March 31, 2026,**<br> **(Unaudited)** | **Variance** | **Variance** |
|  | **2026** | **2025** | $**%** | **%** |
| **Revenues** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Plasma industry | $11748611 | $9409880 |  | 24.9% |
| &nbsp;&nbsp;&nbsp;Pharma industry | 15679452 | 8618653 |  | 81.9% |
| &nbsp;&nbsp;&nbsp;Other | 610361 | 569616 |  | 7.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenues** | 28038424 | 18598149 |  | 50.8% |
| **Cost of revenues** | 9819479 | 6907321 |  | 42.2% |
| **Gross profit** | 18218945 | 11690828 |  | 55.8% |
| **Gross margin %** | 65.0% | 62.9% |  |  |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 8914654 | 7400759 |  | 20.5% |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 2636156 | 1801003 |  | 46.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** | 11550810 | 9201762 |  | 25.5% |
| **Income from operations** | $6668135 | $2489066 |  | 167.9% |
| **Other income** | $800863 | $762198 |  | 5.1% |
| **Net income** | $5438918 | $2586100 |  | 110.3% |
| **Net margin %** | 19.4% | 13.9% |  |  |

---

The increase in total revenues of $9,440,275 for the three months ended March 31, 2026 compared to the same period in the prior year consisted primarily of a $2,338,731 increase in plasma revenue, a $7,060,799 increase in pharma revenue and a $40,745 increase in other revenue. The increase in plasma revenue was primarily due to 89 net plasma centers added during the prior twelve-month period and an increase in plasma donations and dollars loaded to cards as the market appears to have returned to normalized growth following elevated plasma inventory levels experienced throughout much of 2025. The increase in pharma revenue was primarily due to the financial benefit of 45 net pharma patient affordability programs launched during the prior twelve-month period, and a corresponding increase in monthly management fees, setup fees, claim processing fees and other billable services such as dynamic business rules and call center support. For the three months ended March 31, 2026 the number of claims processed increased approximately 49% compared to the same period in the prior year. The increase in other revenue was primarily due to the growth and usage in the number of cardholders of our payroll, retail and corporate incentive programs.

Cost of revenues for the three months ended March 31, 2026 increased $2,912,158 compared to the same period in the prior year. Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, call center support, program implementation and sales and commission expense. The increase in cost of revenues consisted primarily of (i) increased call center support expense of approximately $901,000 associated primarily with the growth in our plasma and pharma patient affordability businesses, a new customer service contact center, wage inflation pressures, a tight labor market and increased benefit costs; (ii) increased sales and commission expense of approximately $266,000 related to the increase in overall revenue for programs in which we pay commission expenses; and (iii) increased network and network related fees of approximately $1,767,000 associated with the addition of 89 net plasma centers and 45 net pharma patient affordability programs. These increases were offset by a decrease in plastics, collateral and postage of approximately $14,000 and other costs of approximately $7,000.

Gross profit for the three months ended March 31, 2026 increased $6,528,117 compared to the same period in the prior year resulting primarily from the launch of an additional 45 net pharma patient affordability programs during the prior twelve-month period, and a corresponding increase in setup fees, monthly management fees, claim processing fees and other billable fees. Gross profit also benefited from the addition of 89 net plasma centers during the prior twelve month period, and corresponding revenue and beneficial impact of a variable cost structure, as many of the plasma transaction costs are variable in nature and are provided by third parties who charge us based on the number of active cards outstanding and transactions that occurred during the period. The increase in gross profit was offset by increased costs from network fees, third-party service providers, sales commission expense and customer service costs mentioned above, primarily driven by the overall growth in our business. The increase in gross margin resulted primarily from a greater contribution of total revenue from our pharma patient affordability business which has higher gross profit margins than our other businesses.

Selling, general and administrative expenses for the three months ended March 31, 2026 increased $1,513,895 compared to the same period in the prior year and consisted primarily of an increase in (i) compensation and benefits of approximately $180,000 due to continued hiring to support our growth, a tight labor market and increased benefit costs; (ii) stock-based compensation of approximately $612,000 related to the issuance of restricted stock units for new hires and employee retention; (iii) technologies and telecom expense of approximately $81,000 primarily related to ongoing platform security investments; (iv) general expenses of approximately $177,000 primarily related to rent, conferences, deliveries and employee education; (v) other expenses of approximately $70,000 primarily related to insurance and outside professional services; (vi) travel and entertainment of approximately $97,000; and (vii) a decrease in capitalized platform development costs of approximately $406,000. The rise in costs was offset by a reduction in acquisition costs of approximately $108,000 associated with the Gamma Innovation LLC ("Gamma") acquisition that closed on March 19, 2025 (see "Note 2 –ACQUISITION" in the notes to the accompanying condensed consolidated financial statements).

Depreciation and amortization expense for the three months ended March 31, 2026 increased $835,153 compared to the same period in the prior year. The increase in depreciation and amortization expense was primarily due to the amortization of intangible assets from our Gamma acquisition, continued capitalization of new software development costs and equipment purchases related to continued enhancements to our processing platform and employment growth.

For the three months ended March 31, 2026, we recorded income from operations of $6,668,135 representing an improvement of $4,179,069 compared to income from operations of $2,489,066 during the same period in the prior year related to the aforementioned factors.

Other income for the three months ended March 31, 2026 increased $38,665 primarily due to higher average bank account balances offset by the implied interest expense related to future cash payments for the Gamma acquisition of $136,884 and slightly lower interest rates.

At March 31, 2026, our income tax expense for federal, state and local taxes totaled $2,030,080, representing an effective tax rate of 27.2%. At March 31, 2025, our income tax provision was $665,164, representing an effective tax rate of 20.5%. Both rates were based on our net operating income adjusted for discrete items that occurred within the quarter and tax benefits related to our stock-based compensation. The significant driver in the discrete item adjustment primarily related to the increase in stock price at March 31, 2026 when compared to the same period in the prior year.

The net income for the three months ended March 31, 2026 was $5,438,918, an improvement of $2,852,818 compared to the net income of $2,586,100 for the three months ended March 31, 2025. The overall change in net income relates to the aforementioned factors.

***Key Performance Indicators and Non-GAAP Measures***

Management reviews a number of metrics to help us monitor the performance of and identify trends affecting our business. We believe the following measures are the primary indicators of our quarterly and annual revenues:

Gross Dollar Volume Loaded on Cards: Represents the total dollar volume of funds loaded to all our prepaid card programs. Our gross dollar volume loaded on cards was $514 million and $407 million for the three months ended March 31, 2026 and 2025, respectively. We use this metric to analyze the total amount of money moving into our prepaid card programs.

Conversion Rates on Gross Dollar Volume Loaded on Cards: Represents revenues, gross profit or net income conversion rates of gross dollar volume loaded on cards which are calculated by taking our total revenues, gross profit or net income, respectively, as a numerator and dividing by the gross dollar volume loaded on cards as a denominator. As we derive a number of our financial results from cardholder fees, we utilize these metrics as an indication of the amount of money that is added to cards and will eventually be converted to revenues, gross profit and net income. Our total revenue conversion rates for the three months ended March 31, 2026 and 2025 were 5.45% or 545 basis points ("bps"), and 4.57% or 457 bps, respectively, of gross dollar volume loaded on cards. Our total gross profit conversion rates for the three months ended March 31, 2026 and 2025 were 3.54% or 354 bps, and 2.87% or 287 bps, respectively, of gross dollar volume loaded on cards. Our net income conversion rates for the three months ended March 31, 2026 and 2025 were 1.06% or 106 bps, and .64% or 64 bps, respectively, of gross dollar volume loaded on cards.

Management also reviews key performance indicators, such as revenues, gross profit, operational expenses as a percentage of revenues, and cardholder participation. In addition, we consider certain non-GAAP (or "adjusted") measures to be useful to management and investors evaluating our operating performance for the periods presented and provide a financial tool for evaluating our ongoing operations, liquidity and management of assets. This information can assist investors in assessing our financial performance and measuring our ability to generate capital for deployment and investment in new card programs. These adjusted metrics are consistent with how management views our business and are used to make financial, operating and planning decisions. These metrics, however, are not measures of financial performance under GAAP and should not be considered a substitute for revenue, operating income, net income, earnings per share (basic and diluted) or net cash from operating activities as determined in accordance with GAAP. We consider the following non-GAAP measures, which may not be comparable to similarly titled measures reported by other companies, to be key performance indicators:

"EBITDA" is defined as earnings before interest, income taxes, depreciation and amortization expense and "Adjusted EBITDA" reflects the adjustment to EBITDA to exclude stock-based compensation expense. A reconciliation of net income to Adjusted EBITDA is provided in the table below.

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  | **2026** | **2025** |
| **Reconciliation of Adjusted EBITDA to net income:** |  |  |
| **Net income** | $5438918 | $2586100 |
| Income tax provision | 2030080 | 665164 |
| Interest income, net | (800863) | (762198) |
| Depreciation and amortization | 2636156 | 1801003 |
| **EBITDA** | 9304291 | 4290069 |
| Stock-based compensation | 1284003 | 672318 |
| **Adjusted EBITDA** | $10588294 | $4962387 |

---

"EBITDA margin" is defined as earnings before interest, income taxes, depreciation and amortization expense as a percentage of the Company's revenue and "Adjusted EBITDA margin" reflects the adjustment to EBITDA margin to exclude stock-based compensation expense as a percentage of revenue. A reconciliation of net income margin to Adjusted EBITDA margin is provided in the table below.

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  | **2026** | **2025** |
| **Reconciliation of adjusted EBITDA margin to net income margin:** |  |  |
| **Net income margin** | 19.4% | 13.9% |
| Income tax provision | 7.2% | 3.6% |
| Interest income, net | (2.9%) | (4.1%) |
| Depreciation and amortization | 9.4% | 9.7% |
| **EBITDA margin** | 33.2% | 23.1% |
| Stock-based compensation | 4.6% | 3.6% |
| **Adjusted EBITDA margin** | 37.8% | 26.7% |

---

**Liquidity and Capital Resources**

The following table sets forth the major sources and uses of cash:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,**<br> **(Unaudited)** | **Three Months Ended March 31,**<br> **(Unaudited)** |
|  | **2026** | **2025** |
| Net cash provided by (used in) operating activities | $18785758 | $(6033177) |
| Net cash used in investing activities | (2075341) | (4443855) |
| Net cash used in financing activities | (2199677) | (375786) |
| Net increase (decrease) in cash and restricted cash | $14510740 | $(10852818) |

---

 

*Comparison of Three Months Ended March 31, 2026 and 2025*

 

During the three months ended March 31, 2026 and 2025, we financed our operations through internally generated funds.

Operating activities provided $18,785,758 of cash as of March 31, 2026, an increase of $24,818,935 compared to the same period in the prior year. This change in cash flow compared to the change in cash flow in the prior period is primarily due to net increases in operating assets and liabilities. The changes in accounts receivable, accounts payable, and customer card funding, a net increase of $22,045,295, are primarily related to the growth in our pharma patient affordability business and timing of pass-through payments as we are invoiced by third-party service providers at the end of the period and are due monies from our pharma patient affordability customers to cover these third-party payables. The increase in cash flow from operating activities was also attributed to an increase in net income and non-cash adjustments for depreciation and amortization, deferred income tax, stock-based compensation and lease expense; offset by an increase in prepaid expenses and other current assets.

We used net cash in investing activities during the three months ended March 31, 2026 and 2025 of $2,075,341 and $4,443,855, respectively. For the three months ended March 31, 2026, cash was used for investing activities primarily attributable to an increase in licenses, fixed assets and capitalization of internally developed software as we continue to invest in our technology platform. For the three months ended March 31, 2025, $2,443,855 in cash was used for investing activities primarily attributable to an increase in software licenses, fixed assets and capitalization of internally developed software as we continue to invest in our technology platform. The remaining amount of $2,000,000 was used for the Gamma acquisition.

For the three months ended March 31, 2026, financing activities resulted in a net cash outflow of $2,199,677, driven primarily by a $2,000,000 contract liability payment related to the Company's acquisition of Gamma. The remainder reflects taxes paid in connection with the net settlement of vested equity awards, for which 56,247 shares of common stock were withheld at a weighted average price of $3.55 per share. For the comparable prior-year period ended March 31, 2025, financing activities resulted in a net cash outflow of $375,786, attributable solely to the repurchase of 100,000 shares of common stock at a weighted average price of $3.76 per share.

Our significant contractual cash requirements also include ongoing payments for lease liabilities and acquisition. For additional information regarding our cash commitments and contractual obligations, see "Note 2 – ACQUISITION" and "Note 5 – LEASE" in the notes to the accompanying condensed consolidated financial statements.

***Sources of Liquidity***

 

At March 31, 2026, our available cash on hand, excluding restricted cash was $20,545,119, an increase of $13,698,098 compared to the same period in the prior year, driven primarily by improvements in our operating results. We believe this cash position, together with our forecast for revenues and cash flows for the remainder of 2026 and through the first quarter of 2028, will be sufficient to sustain our operations for the next twenty-four months. In light of the recent bank failures, we continue to monitor the health and soundness of our bank relationships through publicly available information. Based on recent SEC filings, we have not discovered any issues that would cause us to alter our bank relationships.

***Critical Accounting Policies and Estimates***

 ****

Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Our estimates are based on our experience and our interpretation of economic, political, regulatory, and other factors that affect our business prospects. Actual results may differ significantly from our estimates.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk.**

Because we are a smaller reporting company, we are not required to provide the information called for by this Item.

**Item 4. Controls and Procedures.**

***Disclosure Controls and Procedures***

 

Disclosure controls and procedures means controls and other procedures that are designed to ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and to ensure that information required to be disclosed by us in those reports is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our chief executive officer and chief financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2026. Based on that evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective as of March 31, 2026, the end of the period covered by this Quarterly Report on Form 10-Q.

***Changes in Internal Control over Financial Reporting***

 

During the quarter ended March 31, 2026, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings.**

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not currently a party to any pending or threatened legal proceedings that we believe could have a material adverse effect on our business or financial condition.

**Item 1A. Risk Factors.**

Because we are a smaller reporting company, we are not required to provide the information called for by this Item.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

During the quarter ended March 31, 2026, we did not issue shares of common stock that were not registered under the Securities Act of 1933.

***Issuer Purchases of Equity Securities***

The following table sets forth certain information relating to the purchases of our common stock by us and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) under the Exchange Act during the three months ended March 31, 2026.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number of Shares Purchased** | **Weighted Average Price Paid Per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)** | **Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs** |
| January 1, 2026 – January 31, 2026 |  |  |  | $3001285 |
| February 1, 2026 – February 28, 2026 |  |  |  | 3001285 |
| March 1, 2026 – March 31, 2026 |  |  |  | 3001285 |
| Total |  |  |  | $3001285 \* |

---

\* The dollar value in the above table reflects the original program balance as of March 31, 2026, prior to the May 8<sup>th</sup> 2026 program.

(1) On March 21, 2023, our Board authorized a stock repurchase program to repurchase up to
$5 million of our common stock, subject to certain conditions, through open market purchases, in privately negotiated transactions, or
by other means in compliance with Rule 10b-18 under the Exchange Act. The original program expired March 20, 2026. As of March 31, 2026,
the Company had repurchased 631,258 shares of common stock for $1,998,715 at a weighted average price of $3.17 per share, under the original
repurchase program. On May 8, 2026, our Board authorized a new stock repurchase program to repurchase up to $5 million of our common stock,
subject to certain conditions, through open market purchases, in privately negotiated transactions, or by other means in compliance with
Rule 10b-18 under the Exchange Act, over 36-month period expiring May 7, 2029.

**Item 5. Other Information.**

During the quarter ended March 31, 2026, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" (in each case, as defined in Item 408 of Regulation S-K).

**Item 6. Exhibits.**

---

| | |
|:---|:---|
| 31.1\* | [Rule 13a-14(a)/15d-14(a) Certifications](paysign_ex3101.htm) |
| 31.2\* | [Rule 13a-14(a)/15d-14(a) Certifications](paysign_ex3102.htm) |
| 32.1\* | [Section 1350 Certifications](paysign_ex3201.htm) |
| 32.2\* | [Section 1350 Certifications](paysign_ex3202.htm) |
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101). |

---

______________

**\*** Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
|  | PAYSIGN, INC. |
| Date: May 13, 2026 | */s/ Mark Newcomer* |
|  | By: Mark Newcomer, President and Chief Executive Officer<br> (principal executive officer) |
| Date: May 13, 2026 | */s/ Jeff Baker* |
|  | By: Jeff Baker, Chief Financial Officer<br> (principal financial and accounting officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION**

I, Mark Newcomer, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2026 (the "report") of Paysign, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 13, 2026 | */s/ Mark Newcomer* |
|  | Mark Newcomer,<br> President and Chief Executive Officer<br> (principal executive officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION**

I, Jeff Baker, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2026 (the "report") of Paysign, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 13, 2026 | */s/ Jeff Baker* |
|  | Jeff Baker<br> Chief Financial Officer<br> (principal financial and accounting officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**SECTION 1350 CERTIFICATIONS**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Mark Newcomer, the President and Chief Executive Officer of Paysign, Inc., a Nevada corporation (the "Company"), do hereby certify, to the best of my knowledge, that:

1. The Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the "Report") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| */s/ Mark Newcomer* |
| Mark Newcomer,<br> President and Chief Executive Officer<br> (principal executive officer) |

---

Date: May 13, 2026

This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Paysign, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.

## Exhibit 32.2

**Exhibit 32.2**

**SECTION 1350 CERTIFICATIONS**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jeff Baker, the Chief Financial Officer of Paysign, Inc., a Nevada corporation (the "Company"), do hereby certify, to the best of my knowledge, that:

1. The Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the "Report") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| */s/ Jeff Baker* |
| Jeff Baker<br> Chief Financial Officer<br> (principal financial and accounting officer) |

---

Date: May 13, 2026

This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Paysign, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.